TY - JOUR
T1 - Unfractioned heparin for treatment of sepsis
T2 - A randomized clinical trial (The HETRASE Study)
AU - Jaimes, Fabián
AU - De La Rosa, Gisela
AU - Morales, Carlos
AU - Fortich, Fernando
AU - Arango, Clara
AU - Aguirre, Daniel
AU - Muñoz, Álvaro
PY - 2009/4
Y1 - 2009/4
N2 - OBJECTIVE: The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute Physiology and Chronic Health Evaluation II score, MOD score, and d-dimer. DESIGN: Randomized, double-masked, placebo-controlled, single-center clinical trial, testing low dose continuous infusion of unfractioned heparin (UFH) as complementary treatment for sepsis. SETTING: Five hundred fifty bed University Hospital and referral center in Medellín, Columbia. PATIENTS: Three hundred nineteen patients admitted at the emergency room with signs indicative of sepsis. INTERVENTIONS: Patients were randomly assigned to receive placebo or UFH (500 units/hour for 7 days). MEASUREMENTS AND MAIN RESULTS: The median length of stay in patients discharged alive in the placebo group was 12.5 days (interquartile range = 8-20), and 12 days (interquartile range = 8-19.5) in the heparin group (p = 0.976). The MOD score improved equally in the two treatments arms with an average decline of 0.13 and 0.11 per day for the placebo and heparin groups (p = 0.240), respectively. The overall 28-day mortality was 16% in the placebo group and 14% in the heparin group (p = 0.652). Subgroup analyses did not show any statistically significant reduction in 28-day mortality with UFH. There was only one serious adverse event on a patient who received heparin but it was fully resolved without complications. CONCLUSIONS: Our findings suggested that UFH may be a feasible and safe intervention in sepsis. However, this study was not able to demonstrate a beneficial effect on the chosen primary outcomes or in the 28-day mortality rate.
AB - OBJECTIVE: The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute Physiology and Chronic Health Evaluation II score, MOD score, and d-dimer. DESIGN: Randomized, double-masked, placebo-controlled, single-center clinical trial, testing low dose continuous infusion of unfractioned heparin (UFH) as complementary treatment for sepsis. SETTING: Five hundred fifty bed University Hospital and referral center in Medellín, Columbia. PATIENTS: Three hundred nineteen patients admitted at the emergency room with signs indicative of sepsis. INTERVENTIONS: Patients were randomly assigned to receive placebo or UFH (500 units/hour for 7 days). MEASUREMENTS AND MAIN RESULTS: The median length of stay in patients discharged alive in the placebo group was 12.5 days (interquartile range = 8-20), and 12 days (interquartile range = 8-19.5) in the heparin group (p = 0.976). The MOD score improved equally in the two treatments arms with an average decline of 0.13 and 0.11 per day for the placebo and heparin groups (p = 0.240), respectively. The overall 28-day mortality was 16% in the placebo group and 14% in the heparin group (p = 0.652). Subgroup analyses did not show any statistically significant reduction in 28-day mortality with UFH. There was only one serious adverse event on a patient who received heparin but it was fully resolved without complications. CONCLUSIONS: Our findings suggested that UFH may be a feasible and safe intervention in sepsis. However, this study was not able to demonstrate a beneficial effect on the chosen primary outcomes or in the 28-day mortality rate.
KW - Clinical trial
KW - Coagulation
KW - Heparin
KW - Longitudinal studies
KW - Organ dysfunction
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=67650470156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650470156&partnerID=8YFLogxK
U2 - 10.1097/CCM.0b013e31819c06bc
DO - 10.1097/CCM.0b013e31819c06bc
M3 - Article
C2 - 19242322
AN - SCOPUS:67650470156
SN - 0090-3493
VL - 37
SP - 1185
EP - 1196
JO - Critical Care Medicine
JF - Critical Care Medicine
IS - 4
ER -